Smart device for digitally adapting the state of a substance to be consumed

Abstract

The invention relates to a smart device for adapting the consumption of substances in a manner which is specific to the consumer, comprising • a device for receiving an identification and processing a substance to be consumed, • at least one substance to be consumed which can be uniquely identified by means of a sensory characteristic, such as a QR code or a sensor chip, • at least one mobile unit which is worn on the consumer-side and / or near the body, • at least one wireless network communication between all of the users of worn units, • at least one wireless network connection to a central or decentralized data server in order to exchange the data detected on the consumer side, and • at least one interface for medical specialists for evaluating the data detected on the consumer side. The invention additionally relates to an aerosol-forming device.

Description

[0001] Smart device for digitally adjusting the state of a substance to be consumed

[0002] The present invention relates to a smart device for digitally adjusting the state of a substance to be consumed and to a corresponding method.

[0003] One of the preferred substances for the purposes of the present invention is cannabis, in particular medicinal cannabis.

[0004] Medical cannabis can be used to treat various conditions, particularly in cases where conventional medications are insufficient or when serious side effects occur. Scientific studies show that cannabis does not cure any disease or condition, but it can alleviate symptoms or inhibit the progression of a condition. Based on randomized, double-blind, controlled clinical data, cannabinoids have been shown to be therapeutically effective in chronic pain, multiple sclerosis, nausea, vomiting, and appetite reduction, Gilles de la Tourette syndrome, and glaucoma.

[0005] Cannabinoids also show promising results in the symptomatic treatment of hyperactivity, anxiety, and allergies. In addition to medical treatment, patients often experiment with self-medication in various forms. Cannabis is used for conditions such as anxiety, cancer, epilepsy, inflammatory bowel disease, Parkinson's disease, psychiatric disorders, insomnia / sleep disorders, hyperactivity, anxiety disorders, and allergies.

[0006] Dosage varies from patient to patient. It's important to titrate (increase) the dosage slowly, regardless of the product. The focus is on determining the right dose for each individual patient to truly reap the full benefits of medical cannabis. It's better to take several small doses throughout the day to achieve the desired overall result, rather than experimenting with a single high dose. Cannabis can have very different effects on each patient. You should wait until the effects occur (or not). It's best to use the same (low) dose for several days and monitor any effects.

[0007] After a few days, the patient can increase the dose, but only slowly. Wait a few days after each dose increase to assess progress. Within about one to two weeks, patients should be able to determine their own personal dose, which provides the greatest medical effect with minimal side effects.

[0008] By establishing a treatment protocol, an overdose can usually be avoided. If a patient takes too high doses of THC, the side effects mentioned above can occur.

[0009] Some patients experience an unwanted high. This can be prevented by using a lower dosage or increasing the dose slowly over a longer period of time.

[0010] Adverse side effects and risks primarily occur after consuming high doses or when medical cannabis is used in combination with other substances that enhance its effects, such as certain medications. When administered correctly, medical cannabis has no identified toxic effects on patient health. The common acute side effects of high doses of cannabis occur very quickly after consumption and include increased heart rate, decreased blood pressure, dizziness, dry mouth, reddened eyes, increased appetite, mild euphoria (avoid drug high), and decreased alertness after consumption.

[0011] The principles of the present invention are summarized as follows:

[0012] I. Smart device for digitally adjusting the state of a substance to be consumed, comprising a device for receiving an inserted substance to be consumed, which is designed to bring the substance into a consumable state, in particular an aggregate state, wherein the inserted substance to be consumed is identifiable by the device by a sensory feature, such as a QR code or a sensor chip.

[0013] II. Smart device according to point I, wherein the device is connected to a mobile unit, such as a smartphone, which is designed to retrieve data and / or instructions stored for the substance to be consumed via an app or access to a cloud and to execute them via a digital connection to the device.

[0014] III. Smart device according to item I or II, wherein the device and / or the mobile unit is connected to a body-worn device, such as a smart watch or the like, wherein the body-worn device is designed to capture physical and / or chemical data of a person wearing the body-worn device, compare it with the stored data and / or instructions, and interact based on the comparison.

[0015] IV. Smart device according to point I, whereby the substance to be consumed can only be released in predefined quantities, units or periods of time.

[0016] V. Multi-evaporation device comprising a device for evaporating a vaporizable substance and a receiving device for substance containers, wherein the receiving device is designed to receive at least two substance containers simultaneously, which can be alternately connected to the device for evaporation.

[0017] VI. Multi-vaporizer according to item V, wherein the device for vaporizing a vaporizable substance is the device for receiving an inserted substance to be consumed according to one of claims 1 to 4.

[0018] VII. Multi-evaporation device according to point V, wherein the receiving device is designed like a revolver.

[0019] VIII. Multi-evaporation device according to item V, wherein the receiving device is designed like a magazine. IX. Multi-evaporation device according to item V, wherein, in addition to a first carrier for flavors, at least one second carrier for flavors is provided in the device.

[0020] X. Multi-vaporiser according to point IX, wherein the first carrier for flavours and the second carrier for flavours are separate from each other, preferably in two separate components.

[0021] XI. Multi-vaporizer according to item IX or X, wherein the second carrier is positioned so that the created vapor mixture can mix from the aroma of the first carrier and the second carrier.

[0022] In a first embodiment of the first aspect, the present invention relates to a smart device for consumer-specific adaptation of the consumption of substances, comprising a device for receiving, identifying and processing a substance to be consumed, at least one substance to be consumed that is uniquely identifiable by a sensory feature such as a QR code or a sensor chip, at least one mobile unit worn by the consumer and / or close to the body, at least one wireless network communication between all units worn by the user, at least one wireless network connection to a central or decentralized data server for exchanging the data collected by the consumer, at least one interface for medical personnel for assessing the data collected by the consumer.

[0023] An alternative embodiment relates to a smart device for digitally adjusting the state of a substance to be consumed, wherein the device for receiving an inserted substance to be consumed is designed to bring the substance into a consumable state, in particular aggregate state, and is identifiable by the device through a sensory feature, such as a QR code or a sensor chip. A further development of the two above embodiments provides that the device and / or the mobile unit is / are connected to a body-worn device, such as a smart watch or the like, via a wireless data interface, wherein the body-worn device is designed to record physical and / or chemical and / or pharmacological data of a person wearing the body-worn device.to compare with the stored data and / or instructions and to interact based on the comparison, whereby an exchange of data takes place with a central or decentralized data server.

[0024] Furthermore, it is preferred for the smart device if the device is connected to a mobile unit, such as a smartphone, which is designed to retrieve data and / or instructions stored for the at least one substance to be consumed via an app or direct access to a central or decentralized data server and to execute these via a digital connection to the device, as well as to send data obtained via the mobile unit worn close to the body to the central or decentralized data server.

[0025] Another development of the smart device provides that the substance to be consumed can be released by medical professionals in predefined quantities, units or time periods, whereby the active ingredient concentration and the amount of active ingredient released can be regulated by adjusting the temperature or using a nebuliser unit, and the absorption can be monitored by monitoring the inhalation behaviour (duration, depth).

[0026] The smart device according to the invention can further be designed in such a way that the data obtained by the body-near unit and sent via the mobile unit, such as the smartphone, to the central or decentralized data server can be processed there and compared with consumer-specific data typical of the disease or scientific study databases in such a way that the consumer receives a recommendation via the mobile unit, such as the smartphone, with information on the dosage and type of at least one substance for preventing or alleviating acute attacks of the disease, in a temporally close connection with the collected data.Alternatively, the data obtained by the body-near unit and sent to the central or decentralized data server via the mobile unit, such as the smartphone, can be processed there and compared with consumer-specific data typical of the disease or scientific study databases in such a way that the consumer receives a recommendation via the mobile unit, such as the smartphone, with information on the dosage and type of at least one substance to prevent or alleviate permanent disease patterns, in a temporally close connection with the data collected.

[0027] The two aforementioned alternatives can be developed in such a way that the consumer receives the recommendation with information on the dosage and type of at least one substance at definable time intervals.

[0028] A second aspect of the present invention relates to an aerosol-forming device comprising a device for converting at least one substance into an aerosol or a state of aggregation, a receiving device for substance containers, wherein the receiving device is designed to receive at least two substance containers simultaneously, which can be alternately connected to the device for evaporation.

[0029] An embodiment of the aerosol-forming device provides that the device for converting a substance into an aerosol or a state of matter is the device for receiving an inserted substance to be consumed, as described above.

[0030] In an alternative embodiment of the aerosol-forming device, the receiving device for substance containers is designed like a revolver drum and the fill level can be displayed either directly on the substance container or via a display on the aerosol-forming device or via an app.

[0031] Another alternative is an aerosol-generating device in which the receiving device is designed like a magazine, and the fill level can be displayed either directly on the substance container, via a display on the aerosol-generating device, or via an app. A special embodiment provides for the aroma to be vaporized to be selected from the at least two substances contained in the magazine, using the revolver-drum-like mechanism.

[0032] It has been found to be advantageous in the aerosol-forming device according to the invention that the substances can be mixed with one another in a freely selectable ratio controlled mechanically or digitally via the app by the consumer before they are vaporized from a collecting container provided for this purpose, and that they can be processed from at least two substances in a temperature-specific manner by several steam generators within the aerosol-forming device and that a consumer-specific steam mixture can be adjusted.

[0033] Finally, a further development concerns the aerosol-forming device in which the composition of at least two substances mixed together can be stored at least on the smartphone or on the central or decentralized data server and can thus be accessed by other consumers at any time.

[0034] The present invention focuses on the formation of an aerosol from corresponding substances to be consumed. For the purposes of the present invention, "aerosol" includes smoke, vapor, mist, which can be created by evaporation, combustion, etc.

[0035] The substances to be consumed can be in various forms, such as solids, ground solids, liquids, and oils. Solids are usually burned, while liquids are usually vaporized. The conversion of these substances into a suitable aggregate state is achieved using an aerosol-generating device.

[0036] Further objects, features, advantages, and possible applications will become apparent from the following description of non-limiting embodiments of the invention, taken in conjunction with the figures. All described and / or illustrated features, individually or in any combination, constitute the subject matter of the invention, regardless of their summary in the claims or their references. The present invention, in its first aspect, is illustrated in detail in Figures 386-1 to 386-5 and described below.

[0037] In Figure 386-1, a vaporizing device is shown under A (A1 / A2). A1 is a vaporizer, and A2 is a vape pen. These have a QR code reader / device that displays the white. Furthermore, identification could be achieved via sensor technology such as an RFID chip or similar.

[0038] In B, a cartridge / tank is displayed, which is preferably, but not exclusively, already filled. This tank has a QR code, a chip, or similar sensor device attached so that the reader in A1 and / or A2 can identify it. Since the vaporizer is battery-operated, consumption can be blocked via the QR code, RFID chip, or similar device by preventing the battery or vaporizer function from being activated. This could be the case, for example, in the following scenarios, for example but not exclusively: the insertion of an incorrect product, a ban, a medical order, or similar.

[0039] Preferably but not exclusively, A is connected to an app via a mobile device (tablet, mobile phone), preferably via WLAN / Bluetooth or similar.

[0040] Under D this app gives

[0041] 1) Information about person, age, gender, etc.

[0042] 2) Information about the ingredients of the cartridge / tank (THC, CBD, vitamins, minerals, flavors, etc.)

[0043] 3) the GPS accesses the app and provides location information

[0044] 4) Information is provided about the medical findings, any instructions from the attending physician, medical instructions, and dosages.

[0045] 5) a code / a locking and release option is given, this can be automated but also entered externally by third parties

[0046] In Figure 386-2, A indicates the physician or medical facility that can enter and optimize orders via the cloud or access to the patient's app. These orders are stored as orders on the mobile app (B), in a cloud (C), or directly on the vaporizer (C) (vaporizer / PEN).

[0047] The possible deposits, preferably but not exclusively, are made under D1 for the regulation of medicine (e.g. cannabis variety, CBD variety, THC content)

[0048] Under D2, the products that the patient may consume and which function in the devices under C are selected.

[0049] The number of applications per day and over time is stored under D3.

[0050] Under D4, the dose is stored with the number of puffs that can be measured using device C.

[0051] Under D5 there are possibilities for the doctor to make adjustments to the dose, medicine etc. based on the patient's development as well as possible communication via physical data delivered via a smart device, e.g. a smart watch.

[0052] Under D6, reminders can be installed with an alarm according to the prescribed intake.

[0053] Under D7, alarm devices can be installed which, for example, indicate a rapidly rising blood pressure, this is only an example of the possible display via a smart device / smart watch

[0054] In Figure 386-3, A defines the user or doctor who can attach or prescribe a smart watch for self-monitoring or for monitoring by the doctor. Using this smart watch, the doctor can monitor and adjust prescriptions and adjust the medical prescription based on the feedback of physical, physiologic, and / or chemical data via smart watch B and / or via a patch C for blood testing, etc. Monitoring under B and C can be recorded simultaneously with consumption, which is communicated digitally, via the vaporization device to the smart watch and / or the mobile phone / app. This allows the medicine to have a direct impact on the physical, physiologic, and / or chemical data. In Figure 386-4, A defines parents, a third party, a government agency, or a medical institution.They can use the app to enter information and issue orders regarding THC content, quantities, and times of consumption. Bans are also possible.

[0055] These are transmitted to the mobile unit / device or cloud (C). Under B, the GPS indicates whether the user is in a prohibited zone. If the user is in a prohibited zone, consumption is prohibited. Free zones are recommended. The prohibitions, information on the content, quantity, and time are transmitted to the vaporization devices (D) via the mobile device or the cloud.

[0056] Figure 386-5 also shows the option of attaching the QR code (C) or chip ID to the packaging (A). This is scanned by the mobile device, preferably a cell phone, via the app. This is then forwarded to the stored information as previously described in Figures 1 and 2, as well as 3 and 4.

[0057] The information stored for consumption via the vaporizer is also product-specific and adjusted with regard to optimal temperatures. Furthermore, this information is stored via the QR code / sensor chip, which communicates with the vaporizer by inserting or scanning the packaging. Furthermore, it is possible for the consumer to adjust temperatures to decrease or increase the effectiveness. A doctor could store this information and, for example, allow three puffs at a temperature of 150°C and only two puffs at a temperature of 180°C, which increases the active ingredient content ("puffs" refers to breaths / inhalation).

[0058] The present invention will be further described below with reference to a preferred embodiment. Figure 394-E provides an introduction to the concept:

[0059] The physician (D) (Doctor) has the ability to prescribe and determine medication based on the patient (A) information and the patient findings (A), as well as to check and monitor this medication as well as the patient's physical / chemical data. To do this, the physician (D) prescribes a product / medicine (F) based on the findings, which can be identified by an identifier, such as a QR code and / or a chip. Furthermore, the patient (A) is prescribed or provided with a vaporization device (B2, B3) such as a pen or vaporizer. These devices (B2, B3) are identifiable via a device ID. These devices can be digitally connected to a mobile device (B1), such as a tablet or mobile phone, via Bluetooth, Wi-Fi, or similar. The prescribed dosage and intake of the medication, as well as the dosage specifications, are passed on to (B) via the cloud (G).The vaporization devices (B2, B3) have a reader (X) for reading the QR code and / or RFID chip (F1) attached to the product (F). Verification can also take place via a mobile device (mobile phone, tablet / B1). Using the reader installed in the vaporizer (or via the mobile device B1) and the identification feature (QR code / chip F1) attached to the product / medicine, the device (B3, B2) can recognize the medicine / product (F) used and assign it to the patient using the device's ID. Via access to the cloud (G), the device then follows the instructions / application / order of the doctor (D). The stored medical orders, such as dosage, timing of application, etc., are implemented by the vaporization device (B) only functioning according to the doctor's specified application instructions. Furthermore, the device is programmed to preferably not function if other cartridges and / or unknown QR codes / chips are inserted.

[0060] Under (C2) you can see various measuring devices that the doctor (D) has assigned to the patient (A). C1 is a smart watch, C3 a smart belt, and C21 a smart patch. These devices are intended to be worn by the patient to measure physical and chemical data as well as data from the environment. These devices under (C) are in turn connected to the devices (B) via digital connections such as Bluetooth, Wi-Fi, or similar. This creates a clear connection, particularly in terms of time, between the consumption of the medication by the vaporizer (B) and the physical and chemical patient data (C) measured by the devices C1, 2, and C3. The doctor (D) can track this data precisely and evaluate it statistically. They also have the option of directly intervening in the consumption process and, via the cloud (G), storing new medication, consumption instructions, etc. for the product and the vaporizer using the patient's identification features.

[0061] Figure 394-1 The doctor (F) enters the patient (A1) and his patient information (A2) into the digital cloud / app / server etc.

[0062] The patient (A1) is assigned a vaporization device (B1), which can be assigned via a device ID. This device can optionally be connected to a digital device (tablet, mobile phone, location-based device, etc.) via Bluetooth / Wi-Fi, etc. The digital device stores product information via a QR code / RFID (preferably via cloud access). Based on this information stored via a QR code / RFID chip, the vaporizer can use its integrated reader (QR code, RFID) to assign the information regarding the medication in question and, in conjunction with the vaporizer ID, also implement the patient data and the doctor's instructions.

[0063] (B2) The cloud knows this device and the patient assigned to this device.

[0064] Under C, the physician selects the various ingredients (C1), which are readable via a QR code / RFID affixed to the product. The selection is made based on the patient's diagnosis (C2) and / or the production information (C3).

[0065] Under D, the patient (A1) is provided with a measuring device (D2) that takes measurements (physical and / or chemical) while worn and transmits them to the cloud (E). These measured data are recorded over a 24-hour period, as well as the time and amount of consumption. This allows the physician (F) to view them in the cloud (G) and adjust, optimize, restrict, and block the medication. Production C3 has the option of blocking batches in the event of recalls by entering the information in the cloud (E), and the read QR code / AF ID in the vaporizer no longer functions. At the same time, an alarm message can be triggered via the connected device (D).

[0066] Figure 394-2

[0067] The doctor (11) creates the patient (A) with all possible patient data, medical history as well as origin etc. (A1) After creating the patient (A) and his diagnosis (A1), the doctor prescribes his medical order according to the present invention (these could be time specifications for inhalation, the break between inhalations, time specifications distributed throughout the day and temperature for combustion in the vaporizer). The doctor could also simply set the dose and then issue recommendations for consumption based on the data collected in the cloud.

[0068] At the same time, it would be possible to order / prescribe a smart device such as (smart watch, smart patch, smart belt) to measure the physical and chemical data of the patient and his environment.

[0069] Figure 394-3

[0070] Based on their patient information (A) and their diagnosis (B), the patient (C) receives their prescribed medication according to the present invention. Under D2, D3, D4, they are monitored using various devices (smart watch, smart patch, smart body world, or similar). These devices measure data (E) such as (E1) physical and (E2) chemical data of the patient, as well as (E3) environmental data. Thus, according to E1, blood pressure, body temperature, tremors, or similar could be measured. Under E2, blood values, oxygen levels, THC / CBD levels, or similar could be measured. Under E3, the location and thus the weather conditions, temperature, and humidity could be measured via GPS. Furthermore, information such as the order of new medication, dietary changes, and new clinical pictures could be included for comparison with the data according to E.

[0071] Figure 394-4

[0072] The cloud (A) communicates with the vaporization devices (E) and the connected digital devices (mobile phone, tablet, or similar). The doctor (C) transmits their prescription / order to the cloud, which can be assigned to the patient via the device ID (E), and the prescribed medication, which can be recognized and defined via the QR code / RFID verification between the product / inserted cartridge and the vaporization device reader. Access by the vaporization device or the mobile device (E) connected to the vaporization device enables the implementation of the prescribed medication, dosage, etc., via the doctor (C) and their patient-related data to the cloud (A). According to the doctor's order, the medical prescription could be followed under (F) using information about the product stored in the cloud (A), with the vaporization device (E) implementing the dosage accordingly.

[0073] Under (G) timing and dosage as well as temporal intake sequences with built-in breaks could also be implemented.

[0074] Under (H), possible blocking could also be implemented through a doctor's order, timed notifications, and alerts for consumption via sound or vibration, or similar. Blocking would also be possible for timed consumption of various products, or even blocking due to recalls, which can be defined by QR code / RFID. The device would simply no longer burn that product.

[0075] Figure 394-5

[0076] Under the Cloud (C), data could be collected worldwide, statistics generated, and optimized medications could be derived. The data would be derived from various sources, as follows:

[0077] Measuring devices (A1,2,3) attached in or on the body (A1, an implanted chip, A3 a smart watch or a body belt, A3 a smart patch for measuring blood count and ingredients.

[0078] These would feed the measurement data, both chemical and physical (B1, 2,3) into the cloud database.

[0079] All of this input data would be assigned to the product / medicine as well as the doctor's prescription via the QR code / chip and to the associated vaporization device, assigned via the device's ID.

[0080] This provides the physician (D) with real-time monitoring and long-term statistics on consumption, the product, and the patient's physical and chemical data (D1, D2). Under D3, the physician has the option of adjusting the medication in terms of dosage, timing, etc., based on the received data / information. Under D4, blocking is possible due to a recall of the QR code or product for Zebisch. Furthermore, blocking at certain times or in certain locations / GPS is possible. It is also possible to influence the patient's potential addictive behavior with restrictions or complete blocking.

[0081] Under (E), the patient is monitored over time. This means that the physical / chemical data can be assigned to the time of consumption. Furthermore, the number of puffs, the temperature used, and the time of application are transmitted to the cloud and assigned to the corresponding measurement via the measuring devices under (A).

[0082] By verifying the products via the QR code / chip which is connected to the vaping device / directly or via mobile device.

[0083] This specifies a certain medication and dosage, which can be assigned to the patient via the doctor and the device ID.

[0084] Figure 394-6

[0085] Optimal dosage adjustment could be achieved using algorithms based on the plant / product (A), the vaporization temperature (B), and the number and duration of puffs taken by the patient / consumer. All three components (A, B, C) influence the dose the patient / consumer consumes.

[0086] An example under D1 and D2:

[0087] Under D1, a plant is burned at 150 °C, inhaled with three puffs of 2 seconds each, resulting in the dose ABC.

[0088] If you burn the same plant at 180 °C and consume it with two puffs of 2 seconds each, the resulting dose of ABC is the same.

[0089] If the same plant is burned at 210 °C and a puff is taken for 2 seconds, the same dose ABC will result. These examples are fictitious, but based on the known information that different plants have different THC contents and active ingredients, that they release different strengths of the active ingredient at different temperatures, and that the number and duration of inhalations also determine the dose.

[0090] D2

[0091] If a plant is burned at 150 °C and inhaled three times for 1 second each, we receive dose ABC.

[0092] If we burn the same plant at the same temperature and inhale one puff every 3 seconds, we will receive the same consumed dose of ABC.

[0093] From a medical perspective, it may make sense to administer the medication gradually and with time delays, despite the same dose.

[0094] Figure 394-6.1

[0095] Adjustment of dosage by the doctor

[0096] The doctor could prescribe medicine (C) and medicine 2 (C1). Using the QR codes / chips in the cartridge (C), device A1, the vaporizer, or device A, such as a mobile phone connected to the vaporizer (A1), can assign the product. Using the device ID in devices A and / or A1, the doctor can store the medication and dosage in the cloud, product-specific and patient-specific.

[0097] An application could look like this:

[0098] Application D: D1, one pull for 1 second, pause for 1 minute. D2, one pull for 1 second, pause for 1 minute. D3, one pull for 1 minute, pause / stop for 3 hours.

[0099] In Germany, the application could be implemented in a patient-oriented manner, informing patients about consumption and breaks through sound, vibration, or light effects such as a green or red light. This could also be done via a mobile device, preferably even via voice messages or accompaniment. In the case of a product recall, this could be product-specifically via the QR code / chip, and alarm functions and information could be provided via the mobile device.

[0100] Application F: F1 one train for 2 seconds, pause for 3 minutes. F2 one train for 2 seconds, pause for 3 minutes. F3 stop for 24 hours, locked.

[0101] The patient (G) is monitored in parallel with these applications (D) (E) (F) in terms of his physical and chemical data (smart watch, smart belt, smart patch or similar). This information would be transmitted to the cloud and accessible to the physician, who could monitor and adjust his applications D, E, F.

[0102] Another possibility would be a questionnaire, preferably digital, for the patient (G), which could, for example, provide a score for their well-being before, during, and after consumption, as well as feedback on the effectiveness of the medication and dosage used. This would then be added to the other measured and known data for analysis and statistical purposes.

[0103] The present invention is further described in Figure S 16.

[0104] A

[0105] Under A the vaporization device is indicated, which includes a reader in addition to the vaporization function to identify the product under A1 as well as to identify at least one person in order to enable the product information and dosage stored for the product and for the person (A1) as shown under A2.

[0106] B

[0107] The information for A is stored under B, one steals, which is fed with various information about the patient B1, the product / dosage B2, consumption, when, and what dosage B3, and, if applicable, weather conditions as specified under B4 that could affect the patient's physical and / or chemical data, as well as possible regulations or new regulations under B4. Possible exclusion zones could also be implemented where consumption is not permitted.

[0108] C

[0109] These new details could be stored via the doctor C1, production / possible recall or similar C3, information on weather conditions via the mobile phone that knows / preferably a mobile phone C4, the patient himself, who communicates his medical condition and well-being C6, data collected on courses of study and information about the patient C5, another connected device C2, which carries out chemical and physical measurements on the patient, this one preferably also connected to device A, the vaporization device, in order to measure the physical and chemical data during the vaporization / consumption of the medication.

[0110] C2 could be a device such as a smart watch, a measuring device in the form of a belt, an RFID chip, a functional patch or similar.

[0111] Most unwanted side effects of medical cannabis can be avoided by:

[0112] • start with a low dose - it is better to take several small doses a day;

[0113] • wait and check the effect

[0114] • take the same (low) dose for several days and observe any side effects that may occur;

[0115] • increase the dose slowly, preferably over a longer period of time, so that you can determine the optimal dose;

[0116] The use of medical marijuana has already been proven effective and free of side effects by several studies. Determining the correct dosage remains a major challenge for physicians and their patients. With conventional medications in the form of tablets, capsules, etc., dosage is straightforward for physicians. When consuming medical cannabis, especially when vaporized, the difficulty of controlling the release of the active ingredient is particularly significant. However, this is very important in order to treat the patient with as few side effects as possible and to alleviate symptoms or treat the disease. The dosage varies from patient to patient. Furthermore, contraindications and pre-existing medical conditions must also be considered. Our innovative application method has made it easier to solve this problem.

[0117] The doctor prescribes a vaporizer for the patient, which is assigned to the patient via the device ID. Furthermore, the device contains a sensor reader that can identify the cannabis medicine used via a sensory identifier (RFID / QR or similar). This device is connected to a cloud. The doctor can thus prescribe all medically necessary parameters and monitor and control the therapy. To prevent misuse, the device can also be assigned to a specific patient.

[0118] Controllable parameters include the number of puffs, breaks between puffs and doses, and even the vaporization temperature for medical cannabis. To ensure continuous monitoring of the patient and their physical and biochemical parameters, the patient is provided with at least one measuring device in the form of a body belt, a smartwatch, or a needle patch. These are linked to the device ID and thus to the patient. This allows the physician to know in detail how the patient reacts to the respective consumption. They can adjust the parameters accordingly to ensure optimal treatment for the patient with as few side effects as possible.

[0119] This monitoring also provides optimal protection for high-risk patients with conditions such as high blood pressure or heart problems. The physician can intervene immediately or set the device to shut down at a predefined value, preventing the patient from using it for the time being. By collecting all data from various patients worldwide via a cloud, indications and dosage can be improved, and contraindications and risk factors can be avoided. At the same time, the physician can benefit from the project by participating in studies.

[0120] The device according to the invention is, in particular, a medical application device that is assigned to a patient via a device ID and, via a cloud, allows the physician to monitor and adjust the patient's dosage. Simultaneous monitoring of the patient's physical and chemical data is optionally possible via a further measuring device assigned to the patient. In addition to the first aspect described above, reference is made below to the second aspect, which builds upon and includes it, particularly through the description of the figures.

[0121] Figure 401-1

[0122] Two alternative vaporization devices are shown under A and B. Both vaporization devices have the option of accommodating multiple product cartridges, i.e. devices for vaporizing a vaporizable substance. In Figure A, a revolver device is described under 1. B1 is a plug-in device with the option of plugging in at a specific time. These are two possible designs. The basic idea is to attach multiple product cartridges (active ingredient) (C, C1, C2), at least two in number, to one vaporization device and to provide the option of vaporizing them, as well as selecting them and thus vaporizing them separately, as well as influencing the type of vaporization. Furthermore, the following describes options for vaporizing different products simultaneously and thus enabling a mix of flavors, active ingredients, or similar.

[0123] The selection of the products used for vaporization could be done through a viewing window and manually by pressing a button or using a revolver-type device. These would be physical devices and activation of the vaporization.

[0124] Figure 401-2

[0125] Figure 2 shows, on the one hand, the physical activation with the previously described rotating mechanism, similar to a revolver, under A1, under A and B. Under B2, the selection of products in the (magazine-like) plug-in device would be activated with button activation mechanisms. These explanations are merely examples. The basic idea is to be able to insert at least two cartridges (E) into a vaporization device and activate them for vaporization as selected.

[0126] C and D indicate the possibility of connecting the vaporizer to a mobile device (tablet, mobile phone, or similar). The product cartridges inserted into the vaporizer would be displayed on the mobile device's display (C / D).

[0127] The identification of the inserted product cartridges (E) would work via QR codes or RFID chips attached to the product cartridges. A dedicated reader (A2) is installed in the vaporizer, which can identify the inserted products. These digitally identified products are then preferably communicated to the mobile devices (tablet, mobile phone) (C / D), preferably via the device ID of the vaporizer. This allows the user to mix different active ingredients, flavors, vitamins, THC, and CBD varieties, selectively activate them, and adjust the percentage for each active ingredient.

[0128] Figure 401-3

[0129] In sketch D, an evaporator can be seen which has a reader (D1, D2, D3) for the identification features (ABC) attached to the product cartridges (A, B, C).

[0130] The vaporizer D is connected to the mobile devices via Bluetooth, Wi-Fi, or similar. An app and / or a cloud now offer the digital option of activating various products / product cartridges on the display (E). ABC is shown on the display; these are the cartridges (A / B / C) inserted into the vaporizer (D), read by the reader (D1 / D2 / D3) and digitally communicated to the mobile device (E). In example (E), the option is provided to activate or disable product cartridges.

[0131] In E1 there is the digital option via display to enter percentage settings for each product cartridge used.

[0132] In E2 there is a warning / alert under C. This could be a recall from the manufacturer or a defect in the cartridge.

[0133] For all settings, a saving button can be pressed to save the selection. The cartridge selection, combustion, percentage, or similar is then saved in a saving list. Consumption could also be digitally measured for at least one cartridge. If multiple cartridges are consumed, the consumption would be added together. Preferably, but not exclusively, the following would be measured: duration of consumption (e.g., 1.2 hours / day 1, 35 minutes day 2), amount of active ingredients consumed (THC, nicotine, shisha vape vapor, vitamins & minerals, etc.).

[0134] These could be used for statistical purposes and optimization. Monitoring for smoking cessation could also measure and monitor the duration of consumption or the consumption of active ingredients, optimizing or adjusting the data if necessary (blocking, restricting, specifying amounts and times, etc.). Measurements of the legal maximum consumption could also be taken and compared with the requirements of the respective country / location. Here, a consumption plan could be digitally created and implemented based on the legal or prescribed amount (e.g., if the prescribed amount is 90 grams for 30 days, our device would only allow 3 grams per day of consumption (3 grams x 30 days = 90 grams) or issue an alert / message to the user).

[0135] Figure 401-3.1

[0136] In E3, a display shows various mixing devices, which show different options for the saved settings in Figure 3. These are now on the Saving List and can be selected at the touch of a button without changing the settings. (E3)

[0137] E4 gives you the opportunity to send recommendations from your Saving List to friends

[0138] E5 shows possible fuel levels for each cartridge.

[0139] E6 offers the option of reordering and paying online for tank information that is empty or close to empty.

[0140] Figure 401-4

[0141] Under A, you can see a vaporizer, and under B, three cartridges with different THC concentrations. Vaporizer A is connected to a mobile device (A1) / mobile phone / tablet or similar device via Bluetooth, Wi-Fi, or similar. Based on a medical diagnosis, the doctor (C) prescribes a THC cartridge, preferably several, but each one customized to the diagnosis. These dosages could preferably be stored by the doctor in the cloud, and a better result could be achieved by mixing different plant extracts.

[0142] Under (D), this option could be used to conduct studies to improve the medical applications of various extracts in the correct dosage. The results of the mixture, as well as the patient's well-being, would be stored in a cloud for optimization and statistical purposes.

[0143] Automated settings are also possible under E. These would include, for example, selecting places where smoking is prohibited.

[0144] Furthermore, the time setting could be adjusted on a product-specific basis. For example, medications or cannabis plants that are active should not be smoked in the evening. Excessive consumption can also be blocked.

[0145] Figure 401-4.1

[0146] An extension of the description of Figure 4 is summarized here. A (A) The vaporizer accommodates various product cartridges (B 1 , 2 , 3 , 4) in its receptacles (A 1 , 2 , 3 , 4), preferably as ordered by the physician. As already described, these cartridges are read by a reader using their identification feature and then digitally communicated via WLAN and / or Wi-Fi to a mobile device and / or to a cloud (F).

[0147] Furthermore, the physician (E) preferably stores an order for medication and its administration in the cloud (F). The cloud (F) communicates this to the vaporization device (A) (preferably via mobile device). The device (A) is assigned to a patient by its device identification number. This allows the physician to store various patient- and product-specific mixtures and instructions for consumption in the cloud.

[0148] The instructions (D) are implemented digitally and preferably monitored weekly, and also changed as needed. One possible embodiment, but not limited to, is weekly monitoring (C) and the possibility of adjustment, as examples under C1 and C2. Under C1, one product cartridge is released for consumption each week. This provides an overview of which product cartridge has the best effect on the patient (G). This is monitored by measuring devices that can be assigned to the patient and the vaporization device. These include, but are not limited to, a smart watch, a body belt, and a smart patch. These devices measure the patient's chemical and physical data both at the time of consumption and throughout the day. Furthermore, the patient communicates with the doctor about their well-being and the effects.This could also be implemented instead of a personal interview with a digital questionnaire, preferably with a points-based well-being program.

[0149] Under D2, the doctor (E) has the option of changing the application, for example in the form of the number of inhalations, time of inhalation, temperature of the vaporizer during inhalation, breaks between inhalations, daily application, type of active ingredient.

[0150] The second aspect of the present invention is supplemented by a sub-aspect relating to a multi-vape, i.e. a vaporization device for multiple substances.

[0151] status quo

[0152] There are currently many vape devices for vaporizing nicotine-containing and non-nicotine-containing substances that are chemically enriched with flavors for better taste.

[0153] The market is divided into disposable and reusable vapes. The vaporized ingredients are applied to a carrier material consisting of glycerin, propylene glycol, and nicotine (also available as a nicotine-free version). Flavorings are also added.

[0154] problem

[0155] Especially with disposable vapes, the only option is to consume pre-made flavors. Furthermore, flavors may require different temperatures for optimal consumption. Especially with disposable vapes, the consumer doesn't have the option to actively change flavors.

[0156] Solution

[0157] The present invention is intended to solve this problem and to make an active change that is possible at any time.

[0158] For this purpose, two carriers are used, applied separately. The first carrier is preferably for glycerin, propylene glycol, and possible nicotine enrichment, while the second carrier is enriched with the flavors.

[0159] The flavor carrier is interchangeable in the inventive designs. This could be achieved with plug-in devices on the top, bottom, or side. The plug-in devices could also create multiple, interlocking, freely selectable flavor variations.

[0160] The aroma strength could also be adjusted using manual or digital devices. This could be regulated, for example, by adjusting the size of the aroma tray's airflow.

[0161] In the following, direct reference is made to the figure.

[0162] Figure 451-6 in A shows another way of providing multiple flavorings via carrier materials. Carrier 1, containing glycerin, propylene glycol, and nicotine, is shown here. This is heated by a battery-powered mechanism via electrical devices. D, D1, and D2 show the carriers exclusively for the flavorings. These preferably, but not exclusively (shown here as an example), have an opening on the top through which the flavor can escape and combine with the vapor mixture from E. Preferably, the ventilation flow of openings C, C1, and C2 can be adjusted manually or digitally.

[0163] In B you can see a variant of a revolver device which, as an example, holds three flavor carriers in three chambers, shown here G1, G2, G3, preferably placed in the middle area of ​​the vape device. A cover plate with three openings is placed over this revolver device. The underside of the revolver device can be rotated about its own axis so that all three flavors have free airflow, but one cartridge, two cartridges or all three cartridges can also be closed by rotating the revolver device further about its own axis. If the glycerin, propylene glycol and nicotine are now heated in the carrier area E, the vapor mixture is created which, when the consumer draws through the mouthpiece F, passes the flavor carriers in the revolver device and reaches the mouthpiece. In this way, it absorbs the flavors from the open flavor carriers.

[0164] An embodiment example is described below.

[0165] A known product in the form of at least one product cartridge, preferably also several product cartridges, is provided, wherein these product cartridges are filled with a medicament, preferably a herbal, cannabis, powder product, either ground or in a liquid form.

[0166] This product is attributed to a device that receives information about the product properties of the product used, preferably via a database, in order to then adjust the vaporizer / smoking device. In particular, but not exclusively, the temperature and / or the permitted airflow for consumption are regulated here. A temperature for vaporization / combustion is set, based on the knowledge of the release of the active ingredient of the product used at the temperature used. Furthermore, the dosage is determined based on the knowledge of the released active ingredients, which can be dosed in a controlled airflow / inhalation by the consumer / patient.

[0167] Furthermore, it is possible to adjust the dosage of liquids, for example by injecting a defined amount of liquid from the product cartridge into an evaporation chamber and by combustion / evaporation, which guarantees the known release of the active ingredients at a defined temperature, thereby ensuring a targeted dose.

[0168] In Figure 1, 1 denotes the patient, who is communicatively connected to the physician 10 via a database / cloud. The physician 10 creates the patient under 8 with his or her age, gender, medical record, diagnosis, and prescription, or similar / other information.

[0169] The database also contains general information about the product information / medication / active ingredient, the product properties, particularly in combustion / evaporation and percentage release of the active ingredient in the form of vapor / smoke / aerosol / mist.

[0170] The patient receives a vaporizer / smoking device under 3. This device is provided with an ID assigned to the patient and identifiable by the database. The connection to the database 5 can be established directly or via a mobile device (mobile phone / tablet), preferably via an app.

[0171] Furthermore, at least one product cartridge 2, known via the database of properties, is assigned to the vaporizer / smoking device 3.

[0172] Furthermore, the patient receives a measuring device 4, which monitors the patient's physical and chemical data. These are transmitted to the database in real time or at frequent intervals. This enables monitoring 11 as well as early warning signals, measured chemically and / or physically on the patient, which then communicate medication to the patient, preferably via vibration, sounds, or similar, via the mobile devices. Thus, intake, consumption, or medication can be recommended early based on the early warning signals measured by the measuring device 4.

[0173] The dosage for product 2, consumed via device 3, is stored by the physician 10 in the database 5, as is the prescribed product under 6. The dosage is implemented based on knowledge of the general information 6 and settings related to the combination of product 2 and combustion / vaporization in the vaporizer / smoking device 3. This contains the data on the product and the vaporization of the product at a certain temperature. The dosage is thus determined based on the release of the active ingredient above a certain temperature; these temperature-regulated releases are already known on the market through vape devices and vaporization devices. Another aspect of dosage is the adjustment of the airflow.This is preferably adjusted according to air flow systems known on the market, which regulate the air flow by adjusting the upper opening of the mouthpiece and / or at the bottom of the air flow inlet, this by adjusting the opening elements through which the air flow passes.

[0174] Under 11, the patient is monitored for 24 hours, as well as before, during, and after consumption. This allows for early warning signals of consumption to be communicated, as well as subsequent adjustments to medication.

[0175] This also makes it possible to optimize patient data worldwide.

[0176] Furthermore, two or more product cartridges (number 2) can be inserted into vaporizer 3. This has the advantage that preferred / recommended combinations for consumption in the database are useful for the medication. For example, dual indications in the diagnosis can be treated. For example, Tourette's syndrome and insomnia. These two conditions can be combined, for example, with a combination in the evening before going to bed.

[0177] Furthermore, multiple, different strands can achieve a better effect when combined, or the same effect but with fewer side effects, since the dosages for each medication / active ingredient are kept lower, but as a whole (a combination of three active ingredients, each one third, for example), the same development / symptom treatment is guaranteed.

[0178] Figure II describes the focus of dosage / dose 4.

[0179] The dosage / dose 4 is determined by setting various parameters such as

[0180] 2. the temperature setting

[0181] 3. as well as under the setting of the consuming air flow / set air flow through the vaporization / smoking device

[0182] 1. This is done with knowledge of the product being consumed and the product information stored in the database, such as the active ingredient, percentage of the active ingredient, and known release properties of the active ingredient under chemical and / or physical influences. In particular, this applies to a specific temperature and / or airflow. With knowledge of a fixed constant, the product in the product cartridge 1, and knowledge of the product properties of this product 1 used, particularly under the adjustable physical and / or chemical influence, in particular the temperature 2 and the resulting vaporization / smoke formation / aerosols and the percentage of active ingredient 2 released.

[0183] Knowing the active ingredient concentrations 2, the airflow 3 can be adjusted to deliver a fixed active ingredient concentration for consumption. The airflow setting is the length in time units, the active ingredient concentration in the airflow and the associated consumption of the known active ingredient concentration, and the active ingredient concentration (vapor / smoke formation / aerosol and the known active ingredient concentration).

[0184] The information about the product, product property 1, the information about the active ingredient release and vapor / smoke / aerosol formation for defined temperatures 2, as well as the definition of the created airflow / draft 3 are stored in the database. The vaporizer / smoking device is connected to the database directly or via a mobile phone 6. The reader in the vaporizer / smoking device reads the product cartridge (QR code, RFID, or similar) and can convert all stored information (1, 2, 3) into the dosage information stored by the physician according to the invention.

[0185] In Figure II 1.1, various product cartridges are shown under 1.1. These are preferably, but not exclusively, filled with the same amount of active ingredient. Furthermore, cartridges A / B / C have a sensory identification feature attached. This is preferably, but not exclusively, in the form of an RFID chip or a QR code. These three cartridges A / B / C are then inserted into a vaporizer. This vaporizer reads the sensory feature and can access the database and process the information stored for this product cartridge and this vaporizer. One of these is the time of consumption. Here is an example: A1 / B1 / C1 / consumed at intervals of 6 hours, each at 9:00 a.m. / 3:00 p.m. / 9:00 p.m. In case study 1.1 / 1.3, the entire fill volume is used up. The fill volume is also consumed at a preferred temperature, which is recommended for the product.For example, CBD is heated to 180°C, while THC is preferably heated to 170°C. The dosage times are specifically determined by the physician based on the diagnosis and the patient. Furthermore, the database uses data entered into the database when creating the prescription and dosage instructions. This data provides information about the medical condition and the dosage required to alleviate or eliminate symptoms.

[0186] The interval between doses is determined, and the patient is notified, preferably via a signal, preferably vibration or sound, that they need to take their medication again. The intervals are 6 hours as an example, with 2.5 mg of active ingredient (e.g., THC) being adjusted depending on the patient, diagnosis, and clinical picture.

[0187] If the medication is effective for a pain indication and the patient continues to experience pain, product cartridges with more active ingredient can be prescribed, or the existing product cartridges can be administered at shorter intervals, for example, every 4 hours instead of 6. This increases the dose present in the blood.

[0188] Example 1

[0189] Mr. Müller is a pain patient and receives product cartridges from day 1 to day 7 = three product cartridges to be inserted. The vaporizer signals to take the drug at 9:00 a.m., 3:00 p.m., and 9:00 p.m. The entire amount of active ingredient in the product cartridge is released. The amount released is 2.5 mg.

[0190] After one week, Mr. Müller's pain has lessened, but he still feels some pain. Mr. Müller's doctor is now adjusting his dosage.

[0191] Mr. Müller now receives 5 mg three times a day at 9:00 a.m., 3:00 p.m., and 9:00 p.m. These product cartridges, each containing 5 mg, are provided ready-made to Mr. Müller's consumption.

[0192] Mr. Müller always becomes very tired in the short term after taking 5 mg. The doctor prescribes Mr. Müller 2.5 mg but shortens the intake times by 2 hours. Mr. Müller now consumes more cartridges, at 9:00 a.m., 1:00 p.m., 5:00 p.m., and 9:00 p.m. In 1.2, a vaporization device is shown which can only accommodate one product cartridge. Here, several product cartridges can preferably be prescribed to the patient and, when a signal is given, the patient can insert the product cartridge with the precisely defined amount of active ingredient and smoke. However, as already described, a product cartridge with more active ingredient can also be used. Here, by regulating the temperature and airflow, and the known information about the release of the active ingredient under these known and adjustable parameters (temperature, airflow), the dosage for the patient is delivered as prescribed and stored in the database via the vaporization device and the inserted product cartridge.

[0193] In Figure III.2, under 2.2, a vaporization device with at least two chambers for product cartridges is shown. The vaporization device can read each chamber with a sensor reader via the sensor feature (RFID chip / QR code) attached to the product cartridge. Furthermore, the information about the product cartridge and the active ingredient and product properties (2.1) are stored in database D. Furthermore, the database communicates the stored data on the products, the product properties, and the consumption instructions (vaporization temperature, vaporization duration, airflow setting, these preferably but not exclusively tailored specifically to the product properties) to the vaporization device. To give an example, THC burns best between 170°C and 210°C. This temperature defines not only the release quantity of the active ingredient, but also the ingredients that are released. There are various active ingredients here.

[0194] CBD only begins to release its active ingredient at temperatures above 180°C. If you want to add flavorings for taste, it depends on the specific flavor. These generally burn best between 50°C and 100°C, but this is not the only temperature.

[0195] For this purpose, the information is stored in the database. This information, regarding optimal development, the effectiveness of the active ingredient and flavor, as well as the stored dosage instructions, is passed on to the vaporizer. The vaporizer knows which product cartridges are used via the sensory characteristics of the product cartridge and the reader installed in the vaporizer. This allows the vaporizer to implement this stored information for each product cartridge in terms of temperature, airflow, and duration of vaporization / combustion as stored.

[0196] One example is a blend of THC and CBD, which has proven effective in various studies for pain therapy, symptom management of Tourette's syndrome, and epilepsy. The problem with a blend of both active ingredients in a single product cartridge is the different temperatures. For example, CBD can be burned at 190°C, while THC can be burned at 170°C.

[0197] Example 2

[0198] Pain patient Mr. Müller also can't fall asleep at night. In pain therapy, the active ingredients of many THC active ingredients only develop at 210°C. The THC product cartridge attributed to Mr. Müller is instructed in the vaporization advice database to burn at 210°C. The combustion time and airflow are adjusted to release the specified amount of active ingredient. A CBD cartridge is also used, for which a temperature of 180°C is specified. Furthermore, the dosage settings for the vaporizer are stored in the database using data stored in the product database, including airflow and temperature.

[0199] Mr. Müller takes 10 mg of THC and 15 mg of CBD before bedtime. The product cartridges vaporize independently and autonomously according to the instructions provided in the database, but are preferably, but not exclusively, consumed as a vapor mixture. This could be achieved via an intermediate chamber between the product cartridge and the mouthpiece outlet to the consumer / patient.

[0200] Figure IV.3 shows various product cartridges under A / B / C. These are provided with a sensory feature, preferably but not exclusively an RFID chip and / or QR code. Each product cartridge is filled with a different product / active ingredient.

[0201] These product cartridges are inserted into a vaporizer / smoking device. The inserted product cartridges A1, B1, and C1 can be inserted into any receptacle. The vaporizer uses a reader to identify the sensory feature attached to the product cartridge. This provides the vaporizer with knowledge of the product, the product information, and the stored product properties, particularly with regard to consumption, vaporization, combustion, and release of the active ingredient, via the database.

[0202] The database contains the temperatures best suited for vaporization and / or combustion of the respective products / active ingredients / flowers / flavors. These can be flavors that develop their aromas best at a specific temperature. These can be recommended temperatures for CBD and THC to best release the active ingredient without burning the product. For THC in particular, there are different temperature settings that release different active ingredients. This is particularly important in the medical field and crucial for determining the correct setting and medication for the diagnosis.

[0203] Example 3

[0204] In the given example, Mr. Müller has a THC cartridge A, which is vaporized at 170 °C in the receiving chamber A1, a CBD cartridge B, which is vaporized at 180 °C in the receiving chamber B1, and the product cartridge C, which is filled with aroma, which has the aroma development without burning at 70 °C.

[0205] Information about the vaporization temperatures for the respective products is stored in the database. For THC, it's from 170°C to 210°C, for CBD from 180°C, and for flavors, it's usually below 100°C. Mr. Müller can also mix products himself, enhancing their flavor with active ingredients and flavors. By adjusting the airflow and / or temperature, Mr. Müller can also dose the various product cartridges used via the vaporizer and, if necessary, save them via the database / app.

[0206] This allows patients to participate in Mr. Müller's treatment, as needed or during study programs, by adjusting their settings higher or lower depending on their well-being and symptom relief, and saving the desired results. This can also be done in collaboration with the physician.

[0207] Figure V.4 describes a vaporizer. The active ingredient content under 4.2 is displayed as 0%. A maximum value is set under 4.1, which should not be exceeded. This information is stored in the database; access to the database is provided via the vaporizer or via a mobile phone / tablet or similar device that connects the vaporizer to the database.

[0208] In section 4.3, the desired mean value is shown under M. The mean value is the active ingredient concentration in percent that alleviates or eliminates the patient's symptoms.

[0209] As can be seen from Tables 1 and 2 below, a rapid effect can be achieved through inhalation / vaporization. This effect then lasts for 2 to 4 hours and then decreases again. To ensure consistent efficacy, an average dose is sought. To achieve this, the doses are distributed over time in such a way that the dose decreases, but a desired average dose is maintained when the active ingredient concentration in the patient is always maintained. The following example is provided for this purpose.

[0210] Example 4

[0211] Mr. Müller receives dose 1 at 9:00 a.m. Through inhalation, the effect takes effect after 20 minutes and lasts approximately four hours. After three and a half hours, the effect wears off. At 1:00 p.m., four hours later, dose 2 is taken. This increases the dose again within 20 minutes and lasts for another four hours. A dose is released at 5:00 p.m. Frequent intake is defined in time units that take the product information and active ingredient into account to guarantee an average concentration of the active ingredient in the patient that treats the symptoms. Mr. Müller's dose thus does not fall below a certain level, but also does not exceed a maximum value that would be hazardous to his health.

[0212] Figure VI.5 illustrates a combination of vaporization and oral administration. 5.1 shows the vaporization in its active ingredient curve (DA), while Figure 5.2 shows the oral administration in its active ingredient curve (OR).

[0213] Again, a maximum value is displayed, which should not be exceeded for health reasons. Furthermore, D indicates the zero concentration value. Between the zero value and the maximum value is a medically desired average value, for which a constant concentration must be maintained over a desired period of time.

[0214] Example 5: For this purpose, Mr. Müller receives a vaporizer, which is, of course, connected to the database. This vaporizer is configured by the doctor via the database. The vaporizer vaporizes the product based on the stored data and releases the active ingredient prescribed by the doctor in the prescribed concentration. Through inhalation, the active ingredient takes effect after 20 minutes and lasts for approximately 4 hours.

[0215] Mr. Müller takes this dose, 1 DA / 5.1, at 9:00 a.m. by inhalation. He takes dose 1 OR / 5.2 orally at the same time, at 9:00 a.m.

[0216] The dose inhaled at 9:00 a.m. takes effect after approximately 20 minutes and lasts for 4 hours. The dose taken orally takes effect after 4 hours and lasts for approximately 4 to 8 hours. Thus, Mr. Müller has a constant dose for at least the next 8 hours until 5:00 p.m. The dosage is now repeated with the same amount and the same product combination of oral medication and inhalation (dose 2).

[0217] THC-A CBD-ATHC CBD CBN CBC combustion

[0218] 105°C 120°C 157°C 180°C 185°C 220°C230°C

[0219] Table 1: Vaporization temperature of various cannabinoids: Cannabinoid Vaporizer T emperature

[0220] Parameters Inhalation Oral intake

[0221] Onset of action within seconds to a few minutes after 30 - 90 minutes Maximum effect after about 20 minutes after 2 - 4 hours

[0222] Duration of effect

[0223] 2-3 hours approximately 4 - 8 hours

[0224] Table 2: Type of application and mode of action: onset and duration of action of medical cannabis for inhalation and oral use

[0225] The present invention is described in more detail below in the form of particularly preferred embodiments, specifically with regard to a) the revolver mechanism b) the device referred to here as "MediGuard," which communicates via the database in patient / doctor interaction, whereby the database and the cloud are connected to the smoking device and the measuring device. The database has knowledge of all specified positions as well as the product / active ingredient itself. Everything can be set, adjusted, read, stored, and monitored via the positions. c) the digital setting via a digital device, preferably a mobile phone or tablet, which communicates with the device and digitally receives information about the products. a) the revolver mechanism

[0226] The revolver mechanism is rotated clockwise or counterclockwise into the various usable positions. At least one cartridge, but also multiple cartridges, are possible, which can be rotated in a uniform direction into at least one smoking position. Multiple cartridges are also possible here to create a desired and defined blend of flavors. A viewing window or digital transmission is available to indicate which flavors are being smoked. b) The "MediGuard"

[0227] The MediGuard is a dedicated smoking device with a digital reader for inserting a product cartridge identified by a digital sensor (RFID / QR). This smoking device is assigned to a user / patient. This smoking device is designed to identify the inserted product cartridge. The user / patient is registered with their patient data / physical / chemical characteristics / diseases in an app, cloud, or similar database.

[0228] The product cartridge, with its properties and all product information regarding treatment, chemical and physical properties, is stored in the same database / app / cloud.

[0229] A measuring device for measuring chemical and physical data, assigned to the consumer / patient, is digitally connected to the smoking device and to the cloud / app / database. This measuring device is designed to measure the chemical and physical data of the consumer / patient. The measurements, both individually and in connection with the smoking device, are communicated to the cloud / app / database.

[0230] Access to the database for storage and adjustment by a doctor / hospital / caregiver of the consumer / patient / patient themselves in order to create, monitor, review and change data about the patient, disease progression and medication consumption behavior.

[0231] The database is designed to store the positions of the smoking device, the measuring device, the product cartridge, and the consumer / patient. All data from the created positions communicates with the database and the stored instructions for consumption / smoking / medical use.

[0232] To ensure optimal, precise, and accurate dosing and adjustment for the consumer / patient, the product cartridge's chemical and physical properties, ingredients, and active ingredients are stored. The product used is then digitally read by the smoking device's digital sensor via the cloud, and the smoking device retains all information about the product and the assigned dosage for consumption.

[0233] The consumption is designed and adjustable in that the product is known as follows: in its ingredient in effect, percentage and physical / chemical properties, in its release in the dosage of the active ingredient by temperature-dependent exposure.

[0234] This known dose is then compared with the user / patient data and prescribed dosage. The smoking device and the permitted intake / consumption are adjusted to this dosage, measured by time, duration of consumption, and intensity of consumption / intake, based on the knowledge of the released dosage by exposure to a specific temperature.

[0235] The release of the dosage by temperature is stored for each temperature (linear, exponential) in order to store a dosage by physical adjustment on the smoking device and to allow when to consume, how much airflow can be consumed, what amount and / or time of airflow / outlet is given.

[0236] The interaction of setting the dosage, dispensing through knowledge of the database, the product / product cartridge and thus of the active ingredient, quantity of the active ingredient, dispensing under temperature influence is given.

[0237] The smoking device is digitally adjusted using information stored in the database, adjusted to the temperature and the resulting known release of the active ingredient. The timing and amount of consumption are also digitally adjusted by controlling the airflow and the timing of the airflow. This consumption can also be specified at specific times, for example, morning / midday / evening.

[0238] This allows the physician to submit a defined medical prescription. This prescription can be guaranteed in terms of active ingredient and intake through the described concept. The behavior of the consumer / patient can be monitored, even simultaneously with consumption / during consumption, by measuring their chemical and physical data via the measuring device, which simultaneously stores the measured data in the database of the smoking device. This offers the advantage of being able to adjust medical prescriptions based on the received data. Furthermore, it is possible to collect the data worldwide via a database in order to optimize the medical application. c) Digital adjustment via a digital device

[0239] A smoking device, in particular electronic cigarettes such as vapes and the like, is equipped or can be equipped with at least one identifiable product cartridge, which can be digitally identified using sensor technology.

[0240] This smoking device, digitally connected to another digital device (mobile phone, tablet, or similar), is designed to communicate information about the product cartridges used to this digital device. This information can preferably be read and displayed in an associated app. The display defines the product cartridges. The display offers the option of selecting or deselecting the product cartridges. The display provides the option of mixing each product cartridge with each other. The display offers the option of adjusting the percentage of each individual product cartridge (via a slider, preferably from left to right) to adjust the strength (via digitally applied plus and minus signs or similar). These specified and selected settings are then passed from the mobile device to the smoking device and implemented as instructed.

[0241] The implementation of the digital setting and the adjustment of the strength of consumption can work via different heating elements, and / or by increasing or decreasing the temperature of the individual pressure cartridges, and / or by regulating the aerosol / smoke emitted by their product cartridge, and / or by mixing the flavors in a collecting basin designed for this purpose, in which the added flavors, selected in quantity, are mixed and vaporized.

[0242] Another embodiment is given below.

[0243] Setting the dosage option

[0244] Option 1

[0245] A product cartridge is inserted into the vaporizer / smoking device, the fill volume of which (liquid / solid) is known. Furthermore, the active ingredient content is known, preferably but not exclusively THC / CBD.

[0246] Now, a fixed temperature is set within a recommended temperature range, preferably but not exclusively between 180 °C and 210 °C. For example: 2 g of ground marijuana flower with a known THC content of 5% (5 mg) is poured into the product cartridge.

[0247] This product cartridge is inserted into the vaporizer / smoking device and vaporized / combusted at a set temperature of 175°C. The time taken for the product to be completely consumed is measured. The product cartridge contains 2 g, corresponding to 2 x 5 mg of active ingredient. The total active ingredient is 10 mg. The complete consumption of the used filling quantity (marijuana flower) during vaporization / smoking takes 100 seconds. This equates to an active ingredient content of 0.1 mg per second.

[0248] This allows for dosing with a fixed and released airflow. For example, three airflows lasting three seconds each could release an active ingredient concentration of 3 x 0.3 mg, which corresponds to an active ingredient absorption of 0.9 mg.

[0249] The airflow and air volume chosen can be determined later through blood tests and THC concentration test results. A higher or lower airflow and air volume (volume per ml) can potentially alter bioavailability. This can be determined in studies as described.

[0250] Option 2

[0251] The inserted product cartridge containing a known product (preferably but not exclusively cannabis / THC / CBD) is consumed (vaporized / combusted / consumed / vaporized) at a fixed temperature and a nearly fixed airflow. This airflow is measured using a sensor device according to the respective active ingredient: the proportion and resulting amount of the active ingredient. This proportion is simultaneously measured in a unit of time. Example: per second of airflow, fixed and known, at a nearly fixed temperature and known. The resulting absorbable active ingredient content in the defined airflow can later be used to adjust the patient's dosage.

[0252] Possible evaporation / combustion / but not limited to:

[0253] Heating elements on or in the product cartridge Heatable container in which the product cartridge is inserted Hot air flow passing through the product cartridge past the ground cannabis flower General use of cannabis

[0254] In principle, cannabis can be inhaled or ingested orally. Medical cannabis in its entirety should always be inhaled, smoked, or vaporized with a vaporizer, as this does not produce any potentially harmful substances. THC, the main active ingredient in cannabis, is initially in a pharmacologically inactive form. To convert the THC-A into an active, effective form, the flowers must be heated.

[0255] We recommend using a vaporizer, in which a precisely defined amount of flowers is heated to a controlled temperature of 180°C to 210°C. This creates an aerosol containing active ingredients that is inhaled.

[0256] Compared to inhaled cannabis flowers, the effects of orally ingested cannabis extracts generally take a somewhat longer time to take effect. The slow increase in the active ingredient concentration in the blood and the longer duration of action promote the development of a constant active level in the body. Established indications for medical cannabis

[0257] Established indications for medical cannabis include chronic – especially neuropathic – pain, spasticity in MS, loss of appetite, nausea and vomiting.

[0258] Evidence of positive effects ranges from neurological (spasticity and pain of various causes, hyperkinetic movement disorders) to internal (arthritis, ulcerative colitis, Crohn's disease) and psychiatric illnesses (depression, anxiety disorders, post-traumatic stress disorders, ADHD, sleep disorders), epilepsy, Tourette's syndrome, etc.

[0259] Measuring device from example

[0260] Example 1 :

[0261] Monitoring of the patient's physical and chemical values ​​over 24 hours or more, in conjunction with the set dosage via the implementation of the product cartridge with a defined vaporization / smoking device as described in the invention.

[0262] Preferably, but not exclusively, the vaporization / smoking device is also digitally connected (e.g., via Wi-Fi, Bluetooth, or similar). This has the advantage of explicitly monitoring the patient during consumption of the active ingredient. For example, if blood pressure rises, if body temperature rises, or if blood sugar / insulin levels are monitored, especially for diabetics, the physician has the opportunity to readjust and adjust the patient's treatment. Example 2

[0263] This also provides the opportunity to conduct various study programs, including blind / placebo studies. These include the dosage of the product itself, its active ingredient and active ingredient content, the recommended dosage, the duration of use, the number of daily doses, and the interval between doses.

[0264] These are examples, but not exclusive to the invention. Furthermore, the above-mentioned adjustment options are compared with the patient's well-being, the symptoms to be treated, and their physical condition.

[0265] Dosage of cannabis

[0266] Cannabis should always be dosed gradually at first. Depending on the THC content of the individual strain, the starting dose for flowers should be between 0.25 g and a maximum of 1 g. Depending on efficacy and tolerability, the dose can be increased by approximately 25 mg to 100 mg of cannabis (corresponding to 2.5 mg to 5 mg THC depending on the strain) every 1 to 3 days. The maximum daily dose is 3 g and should not be exceeded. Close consultation with a physician is always required for individual dosage.

[0267] The intake of cannabis extracts and the exact dosage depend on the active ingredient content of the extract, the amount and concentration of the active ingredient released by the vaporization / smoking device, the patient's symptoms, and general information about the patient, including, but not limited to, gender, age, weight, and medical history. To determine the individual dose for optimal therapeutic success, treatment should begin with a lower dosage and be gradually increased over a period of several weeks.

[0268] Dosage example Tourette

[0269] According to the author, treatment of Tourette syndrome with medical cannabis could, for example, begin with a low THC dose of 2.5 mg to 5 mg per day and, depending on efficacy and tolerability, gradually increase to a dose of 10 mg to 20 mg per day. Dosage should be divided into two to three doses per day. There is also initial evidence that administering a combination preparation of tetrahydrocannabinol (THC) and cannabidiol (CBD), such as Sativex®, is beneficial and more effective.

[0270] For this gradual increase in dosage, our invention makes it possible to store the dose increase in the database within a defined time frame, adapted to the patient's information (age, gender, weight, etc.). This allows the prescribed intake to be implemented in accordance with the specifications stored by the doctor in the database via the vaporizer / smoking device and the prescribed product cartridge, whose ingredients and properties are known, in terms of dose, recommended intake, and dose increase, without creating any sources of error during intake by the patient. These are precisely defined by the fixed parameters in terms of dose, intake time, duration, and dose increase according to the specifications in the database.

[0271] Case study Tourette: attitude of patient Mr. Müller

[0272] 1. Mr. Müller receives his vaporizer with product cartridge

[0273] 2. Vaporizer, the prescribed product cartridge and the patient's intake instructions are stored in the doctor's database

[0274] 3. Intake plan as follows

[0275] Day 1 2.5 mg

[0276] Day 2 5mg Day 3 5mg Day 4 5mg Day 5 2 x 5mg (morning / evening) from day 15 2 x 10 mg (morning and evening) Day 15: Feedback from the patient's monitoring device: Blood pressure too high

[0277] Day 16 Doctor changes the prescriptions in the database to 4 x 5 mg

[0278] Day 17: Patient consumes 4 x 5 mg every 4 hours, good tolerability / no increase in blood pressure, relief of Tourette symptoms, positive patient feedback, well-being. From day 18: from a medical perspective, dosage is ideal, relief of symptoms, no medically concerning abnormalities, patient well-being. Result: Patient is considered to be on standby.

[0279] Database is read via Kl and patient data, findings and dosage settings are used to optimize the active ingredient mixture at least two cartridges

[0280] Mixed combinations of active ingredients can also be offered over at least two product cartridges and, depending on the location, study location and monitoring of the database, can be individually adapted to the patient, as well as the location and findings.

[0281] Doses of a CBD and THC mixture have been proven particularly effective in alleviating symptoms of ADHD, epilepsy, and Tourette's syndrome.

[0282] The current study base is still small and weak. Our innovation simplifies various studies and enables them to be initiated worldwide. Artificial intelligence evaluates the information entered into the database by various hospitals and physicians worldwide. This allows for the continuous improvement of data on dosage and indications, based on patient-specific criteria and / or symptoms and findings, and offers patients the best medication and dosage.

[0283] One product cartridge with a known drug release, combined with the vaporizing / smoking device, is used with CBD. A second product cartridge with a known drug release, combined with the vaporizing / smoking device, is used with THC.

[0284] Here, the physician can manually adjust different dosages, or artificial intelligence can divide different studies into study groups and determine the dosages for each cartridge. The data collected from this, regarding well-being, symptom relief, etc., is fed into the database directly via the patient and / or the hospital / doctors.

[0285] The advantage of this device is that the active ingredient mixtures can be adjusted again and again by simply adjusting the consumption approvals and dosage via the database

[0286] early warning system

[0287] Another option for improving the reduction of vaping costs, managing symptoms, and providing medical indications is 24-hour patient monitoring using a device. This device is digitally connected to the vaporizer and simultaneously connected to the vaporizer, a mobile phone, or directly to the database.

[0288] Timely medication

[0289] The measurement involves monitoring physical and / or chemical patient values ​​to enable timely medication.

[0290] This creates the opportunity to store diagnosis-related information that enables early warning of one or more symptoms. This early warning has the advantage of allowing the active ingredient to relieve symptoms to be consumed in advance, preferably via inhalation due to its faster onset.

[0291] There are various early warning bracelets available, especially for Tourette's, which monitor patients and can identify a seizure up to 30 minutes in advance (five out of six patients).

[0292] Here, for example, patient Mr. Müller can receive his pre-set dose (see above) in advance. This can be done via a warning signal function, such as a vibration of the wristband. Early warnings are stored in the database and allow consumption outside of the prescribed dosage and intake instructions.

[0293] Adjusting the dose to a constant mean value

[0294] Here, a medium, medical dosage can be set to achieve a symptom-relieving / alleviating mean value in the patient's blood

[0295] This is achieved by administering a dose at a defined time interval throughout the day to achieve a mean (from - to). This mean is known to eliminate and / or alleviate the patient's symptoms.

[0296] Furthermore, product combinations of inhalation and oral administration can be offered as a combination product. The advantage of inhalation is that the active ingredient develops maximally after 20 minutes, with a duration of effect of 2 to 3 hours. With oral administration, the active ingredient develops maximally after 2 to 4 hours and lasts for 4 to 8 hours. This allows the combination to achieve an overlapping average, since the inhalation ends when the oral administration reaches its maximum effect.

[0297] Setting the vaporizer's temperature correctly is another important aspect of vaporization. A low temperature setting has a completely different effect than a high one. This is due to the fact that the active ingredients vaporize at different temperatures. THC, the main active ingredient in the cannabis plant with its euphoric, pain-relieving, and relaxing effects, vaporizes at approximately 160°C. The second most common active ingredient, CBD, which has an anti-anxiety and muscle-relaxing effects, boils between 160°C and 180°C.

[0298] The sedative and antibiotic CBN evaporates from 186 °C, while the pain-relieving THC-V only evaporates from 220 °C, which is almost no longer evaporation, but already a partial oxidation.

Claims

Patent claims 1. Smart device for consumer-specific adaptation of substance consumption, comprising • a device for receiving, identifying and processing a substance to be consumed, • at least one substance used to be consumed, which is clearly identifiable by a sensory feature, such as a QR code or a sensor chip, • at least one mobile unit worn by the consumer and / or close to the body, • at least one wireless network communication between all user-carried units, • at least one wireless network connection to a central or decentralized data server for exchanging the data collected by the consumer, • at least one interface for medical professionals to assess the data collected by consumers.

2. Smart device for digitally adjusting the state of a substance to be consumed, wherein the device for receiving an inserted substance to be consumed is designed to bring the substance into a consumable state, in particular an aggregate state, and is identifiable by the device through a sensory feature, such as a QR code or a sensor chip 3. Smart device according to claim 1 or 2, wherein the device and / or the mobile unit is / are connected to a body-worn device, such as a smart watch or the like, via a wireless data interface, wherein the body-worn device is designed to record physical and / or chemical and / or pharmacological data of a person wearing the body-worn device, to compare it with the stored data and / or instructions and to interact based on the comparison, wherein an exchange of the data takes place with a central or decentralized data server.

4. Smart device according to one of claims 1 to 3, wherein the device is connected to a mobile unit, such as a smartphone, which is designed to retrieve data and / or instructions stored for the at least one substance to be consumed via an app or direct access to a central or decentralized data server and to execute these via a digital connection to the device, as well as to send data obtained via the mobile unit worn close to the body to the central or decentralized data server.

5. Smart device according to one of claims 1 to 4, wherein the substance to be consumed can be released by medical personnel in predeterminable quantities, units or periods of time and wherein the active ingredient concentration and the amount of active ingredient released can be regulated by adjusting the temperature or by means of a nebuliser unit and the absorption can be monitored by monitoring the inhalation behaviour (duration, depth).

6. Smart device according to one of claims 1 to 5, wherein the data obtained by the body-near unit and sent via the mobile unit, such as the smartphone, to the central or decentralized data server can be processed there and compared with consumer-specific data typical of the disease or scientific study databases, so that the consumer receives a recommendation via the mobile unit, such as the smartphone, with information on the dosage and type of the at least one substance for preventing or alleviating acute attacks of the disease, in a temporally close connection with the collected data.

7. Smart device according to one of claims 1 to 5, wherein the data obtained by the body-near unit and sent via the mobile unit, such as the smartphone, to the central or decentralized data server can be processed there and compared with consumer-specific data typical of the disease or scientific study databases, so that the consumer receives a recommendation via the mobile unit, such as the smartphone, with information on the dosage and type of the at least one substance for preventing or alleviating permanent disease patterns, in a temporally close connection with the collected data.

8. Smart device according to claim 6 or claim 7, wherein the consumer receives the recommendation with information on the dosage and type of the at least one substance at definable time intervals.

9. Aerosol-forming device comprising • a device for converting a substance into an aerosol or a state of aggregation, • a receiving device for substance containers, wherein the receiving device is designed to receive at least two substance containers simultaneously, which can be alternately connected to the device for evaporation.

10. Aerosol-forming device according to claim 9, wherein the device for converting a substance into an aerosol or a state of matter is the device for receiving an inserted substance to be consumed according to one of claims 1 to 5.

11. Aerosol-forming device according to claim 9, wherein the receiving device for substance containers is designed like a revolver drum and the fill level can be displayed either directly on the substance container or via a display on the aerosol-forming device or via an app.

12. Aerosol-forming device according to claim 9, wherein the receiving device is designed like a magazine and the fill level can be displayed either directly on the substance container or via a display on the aerosol-forming device or via an app.

13. Aerosol-forming device according to claim 9, wherein the aroma to be vaporized can be selected from the at least two substances located in the magazine, wherein the revolver-drum-like mechanism is used.

14. Aerosol-forming device according to claim 9, wherein the substances can be mixed with each other in a freely selectable ratio controlled mechanically or digitally via the app by the consumer before they are vaporized from a collecting container provided for this purpose, as well as by several vapor generators within the aerosol-forming device from at least two substances can be processed in a temperature-specific manner and a consumer-specific vapor mixture can be adjusted.

15. Aerosol-forming device according to claim 9, wherein the combination of at least two substances mixed together can be stored at least on the smartphone or on the central or decentralized data server and can thus be accessed by other consumers at any time.

Images